[Effect of silencing connective tissue growth factor on the liver fibrosis in rats]

Guang-ming Li1, Ding-guo Li, Jian-gao Fan

  • 1Department of Gastroenterology, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China. ligm68@126.com

Abstract

Insights

Small interfering RNA (siRNA) targeting connective tissue growth factor (CTGF) effectively reduced liver fibrosis in rats. This approach significantly decreased CTGF and alpha-smooth muscle actin (a-SMA) protein levels and inhibited hepatic stellate cell activation.

Area of Science:

  • Hepatology
  • Molecular Biology
  • RNA Interference Therapeutics

Background:

  • Liver fibrosis is a significant health concern characterized by excessive extracellular matrix deposition.
  • Connective tissue growth factor (CTGF) plays a crucial role in the pathogenesis of liver fibrosis.
  • Hepatic stellate cell (HSC) activation is a key event in liver fibrogenesis.

Purpose of the Study:

  • To evaluate the efficacy of intraportal vein small interfering RNA (siRNA) targeting CTGF in a rat model of liver fibrosis.
  • To assess the impact of CTGF-targeting siRNA on HSC activation and fibrotic markers.

Main Methods:

  • Liver fibrosis was induced in male rats using carbon tetrachloride (CCl4) injections over six weeks.
  • Rats received intraportal vein injections of CTGF siRNA, control siRNA, or saline.
  • Protein expression of CTGF and alpha-smooth muscle actin (a-SMA) was measured by Western blot.
  • Histological analysis using HE and Sirius red staining assessed liver fibrosis and collagen deposition.
  • Immunohistochemistry evaluated the number of active HSCs.

Main Results:

  • CCl4 induction led to significant upregulation of CTGF and a-SMA in control groups.
  • CTGF siRNA treatment markedly reduced CTGF and a-SMA protein levels by 95% and 86%, respectively.
  • A significant decrease (76%) in active HSCs was observed in the CTGF siRNA group.
  • Attenuation of liver fibrosis was evident in rats treated with CTGF siRNA.

Conclusions:

  • Intraportal vein siRNA delivery targeting CTGF effectively inhibits CTGF gene expression in the liver.
  • This targeted inhibition significantly attenuates liver fibrosis by reducing HSC activation.
  • CTGF-targeting siRNA represents a promising therapeutic strategy for liver fibrosis.